Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant.

Scandinavian journal of gastroenterology - 1 Jun 2024

Jönsson Cecilia, Bergram Martin, Kechagias Stergios, Nasr Patrik, Ekstedt Mattias

Abstract excerpt

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition worldwide. There is an urgent need to develop new biomarkers to assess disease severity and to define patients with a progressive phenotype. Activin A is a new promising biomarker with conflicting results about liver fibrosis. In this study we investigate levels of Activin A in patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activins
Share to Acyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Lipase

Share to Liver Cirrhosis

Share to Phospholipases A2, Calcium-Independent

Share to Severity of Illness Index

Source

Identifiers

PMID: 38563432
DOI: 10.1080/00365521.2024.2334804

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activin A levels in metabolic dysfunction-associated steatotic liver disease associates with fibrosis and the PNPLA3 I148M variant.PMID 38563432Read ↗

Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD.Semantic proximity Read ↗

Role of PNPLA3 in Hepatic Stellate Cells and Hepatic Cellular CrosstalkSemantic proximity Read ↗

PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.Semantic proximity Read ↗

The PNPLA3 I148M Variant Is Associated with Immune Cell Infiltration and Advanced Fibrosis in MASLD: A Prospective Genotype-Phenotype StudySemantic proximity Read ↗

Global epidemiology and implications of PNPLA3 I148M variant in MASLD: a systematic review and meta-analysisSemantic proximity Read ↗

Association of PNPLA3 I148M with Liver Disease Biomarkers in Latinos.Semantic proximity Read ↗

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.Semantic proximity Read ↗

The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.Semantic proximity Read ↗

Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis.Semantic proximity Read ↗

Analysis of TM6SF2, PNPLA3, and ATG16L1 Genetic Variants in MASLD and MASH: An Egyptian Case-control StudySemantic proximity Read ↗

Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.Semantic proximity Read ↗

Patatin-Like Phospholipase Domain-Containing Protein 3 rs2896019 and MASLD Susceptibility and Severity in Adults: A Systematic Review and Meta-Analysis of Case-Control Studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.